0.709

7.55% 0.0498

After Hours: .69 -0.019 -2.68%

Pds Biotechnology Corporation (PDSB)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Pds Biotechnology Corporation stock is traded at $0.709, with a volume of 362.01K. It is up +7.55% in the last 24 hours and down -25.36% over the past month. PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Previous Close:

$0.6592

Open:

$0.6528

24h Volume:

362.01K

Relative Volume:

0.56

Market Cap:

$38.80M

Revenue:

Net Income/Loss:

$-40.56M

P/E Ratio:

-0.606

EPS:

-1.17

Net Cash Flow:

$-35.28M

1W Performance:

+5.69%

1M Performance:

-25.36%

6M Performance:

-45.46%

1Y Performance:

-43.73%

1-Day Range:

$0.6506

$0.7256

1-Week Range:

$0.6012

$0.7305

52-Week Range:

$0.6012

$2.20

Pds Biotechnology Corporation Stock (PDSB) Company Profile

Name

Pds Biotechnology Corporation

Sector

Healthcare (1108)

Industry

Biotechnology (621)

Phone

800-208-3343

Address

303A COLLEGE ROAD EAST, PRINCETON

Employee

Twitter

@pdsbiotech

Next Earnings Date

2024-11-12

Latest SEC Filings

PDSB's Discussions on Twitter

Compare PDSB vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PDSB Pds Biotechnology Corporation	0.709	36.07M	0	-40.56M	-35.28M	-1.17
VRTX Vertex Pharmaceuticals Inc	483.05	123.82B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	784.28	81.64B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	816.95	52.00B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	327.36	44.14B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	352.23	40.83B	4.98B	69.60M	525.67M	0.5198

Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-01-22	Initiated	B. Riley Securities	Buy
Jun-28-21	Initiated	Cantor Fitzgerald	Overweight
Nov-10-20	Upgrade	H.C. Wainwright	Neutral → Buy
May-27-20	Initiated	Alliance Global Partners	Buy
Mar-09-20	Initiated	Noble Capital Markets	Outperform
Oct-24-19	Initiated	Chardan Capital Markets	Buy

View All

Pds Biotechnology Corporation Stock (PDSB) Latest News

Feb 24, 2026

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail

Feb 24, 2026

Feb 20, 2026

PDS Biotechnology Amends Late-Stage Trial for PDS0101 to Support Accelerated Approval Pathway in HPV16-Positive Head and Neck Cancer - marketscreener.com

Feb 20, 2026

PDS Biotech amends Phase 3 trial to add accelerated approval path - Investing.com

Feb 20, 2026

LiveRamp Holdings, Inc. has announced a partnership with Scowtt - Bitget

Feb 20, 2026

Nucor has announced that Jack Sullivan has been promoted to Chief Financial Officer, Treasurer, and Executive Vice President of the company. - Bitget

Feb 20, 2026